GeneWriter Inc. is a consulting business with a singular focus: helping advance innovation in the genome editing space through regulatory review to first-in-human clinical trials.

Our team of experts is dedicated to assisting companies and researchers navigate the complex landscape of genome editing regulations.

We understand the importance of your work and the potential impact it can have on society. That's why we provide tailored guidance and strategic advice to ensure your projects meet the necessary requirements and move forward with efficiency and compliance.

The founder of GeneWriter, Inc., Dr. Fyodor Urnov, a Professor of Molecular Therapeutics at UC Berkeley. He co-developed the toolbox of human genome and epigenome editing and led the team that developed a strategy for genome editing in the hemoglobinopathies, sickle cell disease and beta-thalassemia, that has yielded sustained clinical benefit for subjects in several ongoing clinical trials.